World-renowned pharmacologist Dr. Nephi Stella presents his groundbreaking research
Dr. Nephi Stella, Professor of Pharmacology, Psychiatry and Behavioral Sciences at the University of Washington and CEO of Stella Therapeutics shares his findings on the effects of cannabinoid-based molecules on certain devastating types of epilepsy and cancer at this year’s CannaTech Innovation Summit, Israel’s premier international conference for showcasing cannabis innovation, taking place in Tel Aviv, March 20-21, 2017.
Dr. Stella has been studying the medical effects of cannabis for over 20 years and founded his own start-up company in 2011 to expedite the identification and development of novel molecules that treat unmet medical disorders. The core of Stella Therapeutics’ work focuses on anti-tumor properties of cannabinoids (CBD), specifically to treat Glioblastoma multiforme, an aggressive form of brain cancer, plus melanoma metastases. His team at the University of Washington is studying the medical properties of CBD to treat seizures for children with Dravet Syndrome. Dr. Stella was an important influencer and heavily involved in policy making for the legalization of cannabis in Washington state. He is leading efforts to implement a world-leading center for cannabis research at the university to further investigate the plant’s biology alongside its agricultural, medical and social applications.
“By optimizing the medical properties of cannabinoid compounds and targeting enzymes that control the endogenous system, we’ve made remarkable progress with specific molecules,” says Dr. Stella. “Collaborating with the international cannabis community over the next few years, we’re looking to further unlock the cannabis code and make significant advances in understanding the effects of different strains to offer more customized and even personalized treatment.”
Dr. Stella joins other leading cannabis scientists from Israel and around the world presenting their latest findings at CannaTech 2017, powered by iCAN: Israel Cannabis, including Dr. Dedi Meiri of the Technion’s Cancer Research laboratory; Dr Yasmin Hurd, Professor of Psychiatry, Neuroscience and Pharmacological Sciences at Icahn School of Medicine in New York; and Professor Reuven Or of Hadassah Hospital.
“CannaTech is the only industry conference that couples academic research with business, and Israel has become the primary hub for fueling this activity, galvanised by the work of Professor Raphael Mechoulam. It’s an honor to present my work at the event, and I look forward to meeting fellow colleagues to discuss potential partnerships,” adds Dr. Stella.